CIAM
NVCR icon

Caitong International Asset Management’s NovoCure NVCR Stock Holding History

Caitong International Asset Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$392 Buy
36
+5
+16% +$62 ﹤0.01% 1728
2025
Q4 		$401 Buy
+31
New +$398 ﹤0.01% 1512
2025
Q3 		– Sell
-133
Closed -$2.37K – 2339
2025
Q2 		$2.37K Buy
+133
New +$2.32K ﹤0.01% 1329

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Caitong International Asset Management's NVCR Position: Q1 2026 in Review

Caitong International Asset Management increased its NovoCure (NVCR) stake by 16% in Q1 2026, buying an estimated $62 and bringing the position to 36 shares worth $392. The position accounts for ﹤0.01% of the portfolio, ranked #1728.

Caitong International Asset Management first reported a position in NVCR in Q2 2025 and has held it in 3 quarters since. The position peaked at $2.37K in Q2 2025. 223 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • Caitong International Asset Management held 36 shares of NovoCure worth $392 as of Q1 2026.
  • Caitong International Asset Management bought 5 NovoCure shares in Q1 2026, an estimated $62.
  • NovoCure made up ﹤0.01% of Caitong International Asset Management's portfolio in Q1 2026, its #1728 holding.
  • Caitong International Asset Management first reported a position in NovoCure in Q2 2025 and has held it in 3 quarters since.
  • Caitong International Asset Management's NovoCure position peaked at $2.37K in Q2 2025.
  • 223 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.